Tightening The Belt on Biotech Spend: Optimizing Development During a Market Downturn
Summary: Listen in as experts Sherief Shaaban from Catalent and Kurt von Emster of Abingworth discuss taking a drug from concept to a tangible solution with a renewed focus on milestones, timelines, and efficiencies. Learn how biotechs are reconsidering strategic partnerships to better navigate development pathways, accelerate timelines, avoid common pitfalls, and stretch limited capital further than before.